Big pharma often plays “fund, license, kill” - a strategy which requires extreme precision in an industry where missing a competitor or hallucinating a patent number is a never-event.
Andrey Doronichev, CEO, OPTIC | Onyx Live | JPM 2026
Agentic AI makes a big splash in biopharma.
Related
Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Everyone watches the final cell therapy – far fewer watch what the cells are grown in. Compass Biomedical's Kim Brown on why culture media quietly shapes the product.
Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Cell and gene therapy can get treatments approved – scaling them is the hard part. Cellular Origins' Jason Jones on automating manufacturing to reach 100,000 patients a year.
Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Exosomes are "cell therapy without the cells" – and University of Miami's Dimitrios Kouroupis sees these cell-free vesicles reshaping musculoskeletal medicine.
Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.